Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and Type 1 diabetes, both of which are in Phase 2 trials, with data expected in 2018.Read More
Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS).Read More
As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six-year residency in neurosurgery. But since the age of 12, he has had a passion for computer coding and, as a result, contributed to the company’s software development, which aims to capture motion data as a method to diagnose neurodegenerative diseases...Read More
As a member of the Health Law Group at Fasken Martineau in Toronto, Rosario Cartagena provides advice on a variety of health law matters, including corporate governance, public policy, government relations, risk management, privacy, health regulatory compliance, and health research. She also regularly assists in drafting agreements, related to corporate governance and regulatory compliance across the health sector. Prior to obtaining her law degree from the University of Ottawa, Ms. Cartagena completed a graduate degree in Public Health at the University of Alberta and she was also an intern at the Harvard School of Public Health, researching policies and laws around the world, which focused on people living with HIV-AIDS. In this interview with BioTuesdays.com, Ms. Cartagena discusses a Supreme Court of Canada decision in 2015 that declared the existing criminal prohibition on physician-assisted death to be unconstitutional and the proposed legislation, known as Bill C-14, which has come out of that ruling.Read More
Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for Amyotrophic Lateral Sclerosis (ALS) to begin at the end of 2016.
“Our plan is to begin the trial in Israel under an IND and then continue it in the U.S.,” Arik Hasson, EVP for R&D, says in an interview with BioTuesdays.com.
Dr. Hasson explains that Kadimastem’s technology platform enables the differentiation of stem cells into a range of functional human cells for regenerative medicine, including neuron-supporting cells of the brain for diseases of the central nervous system, such as ALS, as well as pancreatic cells that produce and secrete insulin for Type 1 diabetic patients.Read More